Ovarian Cancer

Ovarian tumor xenografts are imaged and treated using sodium iodide symporter-mediated radioiodide

Published in Gene Therapy Weekly, February 16th, 2006

Recent research from the United States has described sodium iodide symporter (NIS)-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.

"Ovarian cancer represents the fifth leading cause of cancer death among women in the United States, with 416,000 deaths expected this year. This study was carried out to investigate the potential of NIS-mediated radioiodide therapy as a novel approach for ovarian cancer treatment," wrote R.M. Dwyer and colleagues, Department of Endocrinology & Internal Medicine.

"Radioiodide is routinely and effectively used for the treatment of benign and malignant thyroid disease as a result of native...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry